Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994338 · ClinicalTrials.gov registry record · Phase 2
Tirzepatide for Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder and Obesity and Overweight, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT06994338: Recruiting Phase 2 study of Alcohol Use Disorder and Obesity and Overweight, sponsored by University of Southern California.
NCT06994338 is a Phase 2 study of Alcohol Use Disorder and Obesity and Overweight that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 42 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06994338, a Phase 2 study of Alcohol Use Disorder and Obesity and Overweight, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Primary Outcome
Number of heavy drinking days (NHDD) during the last four weeks of treatment (treatment Weeks 5-8), as measured by the Timeline Followback interview. NHDD is defined as the total number of days on which participants consumed 5 or more drinks (for men) or 4 or more drinks (for women). The analysis of NHDD will control for baseline NHDD (defined as NHDD in the four weeks preceding treatment).
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Placebo injections
Study Locations (1)
California
- Keck School of Medicine, University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-10-06 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
What NCT06994338 shows while recruiting
NCT06994338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06994338 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06994338 about?
NCT06994338 is a clinical study titled "Tirzepatide for Alcohol Use Disorder". The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
What is the current status of trial NCT06994338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-10-06. Estimated completion is 2026-08-31.
What conditions does trial NCT06994338 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Obesity and Overweight, Alcohol.
What interventions are being tested in trial NCT06994338?
The interventions under investigation include: Tirzepatide (DRUG), Placebo injections (DRUG).
Who is sponsoring clinical trial NCT06994338?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06994338 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06994338's enrollment target sits among peer trials
42 136th of 184 higher than 48 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI